Sermorelin vs SLU-PP-332: how the two actually compare

Last updated 2026-07-24

What are sermorelin and SLU-PP-332, in plain terms?

Sermorelin is a synthetic 29-amino-acid peptide that mimics growth hormone-releasing hormone (GHRH), the signal your hypothalamus sends to the pituitary gland to release its own growth hormone. It was FDA-approved and marketed in the US under the brand name Geref for diagnostic and pediatric growth hormone deficiency use before the manufacturer discontinued it commercially in the mid-2000s ^[1]. That's a real regulatory paper trail, something most peptides sold today simply don't have. SLU-PP-332 is a different animal entirely. It's a small-molecule (not a peptide) developed by researchers at Saint Louis University to activate estrogen-related receptors (ERRα, ERRβ, ERRγ), the same receptor pathway involved in mitochondrial biogenesis and exercise adaptation. The original 2023 study published in Nature Communications found that SLU-PP-332 increased running endurance in mice and shifted muscle fiber composition toward more oxidative, fatigue-resistant fiber types ^[2]. The core difference isn't just mechanism, it's evidence stage. Sermorelin has been in humans, at scale, for decades. SLU-PP-332 has been in mice, in one lab's rodent studies, for a few years. That gap matters more than anything else in this comparison. If you want the fuller picture on how sermorelin works and what it's approved for, see sermorelin.

Sermorelin vs SLU-PP-332: side-by-side comparison

Does SLU-PP-332 have any human research at all?

No. As of the most recent published literature, SLU-PP-332 has not completed a registered human clinical trial. The foundational paper from Billon et al., published in Nature Communications in 2023, describes work exclusively in mouse models ^[2]. There's no Phase 1 safety data, no established human dose, no pharmacokinetic profile in people, and no peer-reviewed human outcomes data. That's not a minor gap. It means anyone taking SLU-PP-332 today is essentially running an uncontrolled personal experiment with a molecule whose human safety margins, drug interactions, and long-term effects are simply unknown. Companies selling it for personal use are doing so outside any regulatory framework; it's typically labeled 'not for human consumption' precisely because the seller has no approval to claim otherwise. Sermorelin, by contrast, has published dosing studies in children with growth hormone deficiency and separate studies in older adults testing GH-axis stimulation ^{[3] [4]}. You can find the actual mg/kg ranges used and the observed effects on IGF-1 levels. That's the difference between an approved-then-discontinued drug and an unapproved research chemical.

Is sermorelin still FDA approved?

No, not as the branded product. Geref (sermorelin acetate) received FDA approval in the late 1980s and early 1990s for diagnostic testing of GH secretion and for treating pediatric growth hormone deficiency. The manufacturer discontinued Geref for commercial reasons in the mid-2000s, not because of a safety recall or an FDA-mandated withdrawal ^[1]. That distinction gets blurred online constantly, and it matters: a drug pulled for business reasons (low sales volume, manufacturing costs, shifting to other GH-axis products) is a very different story than one pulled for adverse events. Today, sermorelin is available in the US primarily through compounding pharmacies, prescribed off-label, under the oversight of the FDA's compounding framework (Sections 503A and 503B of the Federal Food, Drug, and Cosmetic Act). It is not currently an FDA-approved commercial drug product on the market, but it does have that approval history behind it, which no research chemical can claim. For a deeper walkthrough of dosing ranges used in modern off-label protocols, see the sermorelin dosage chart.

How do the mechanisms actually differ in what they do to the body?

Sermorelin works upstream. It binds GHRH receptors on the pituitary gland, prompting the pituitary to release its own stored growth hormone in a pulsatile pattern that roughly mimics natural GH secretion. Because it relies on a functioning pituitary, a built-in negative feedback loop stays intact; if GH and IGF-1 rise too high, the body's own regulation can dial back the response. This is one reason its safety profile in clinical use has been considered manageable in GHD populations ^[4]. SLU-PP-332 doesn't touch the GH axis at all. It's an agonist at estrogen-related receptors alpha, beta, and gamma, receptors that regulate genes involved in mitochondrial density, fatty acid oxidation, and muscle fiber type switching. In mouse studies, activating these receptors pharmacologically produced effects that resembled endurance exercise training, without the mice actually running more ^[2]. It's being researched as an 'exercise mimetic', a compound that tries to reproduce some cellular effects of exercise chemically. So you're not really choosing between two versions of the same tool. You're choosing between a pituitary-stimulating peptide with an approval history, and an experimental receptor agonist from a completely unrelated pathway that has never been dosed in a human being in a published trial.

Which one has better safety data?

Sermorelin, by a wide margin. Clinical literature on sermorelin (including the Geref era and later academic studies) documents injection site reactions, flushing, headache, and dizziness as the most commonly reported side effects, with rare reports of more significant reactions ^[4]. Long-term surveillance isn't as extensive as decades-old drugs like insulin, but it exists, and it's grounded in actual patient data. SLU-PP-332 safety data in humans doesn't exist. Full stop. Everything known comes from rodent studies examining endurance and metabolic markers, not systematic toxicology or long-term safety monitoring in people ^[2]. Anyone claiming to know its human side effect profile is guessing, not citing. For a detailed look at what sermorelin's downsides actually look like over months or years of use, see sermorelin long-term side effects.

Sermorelin vs HGH: where does sermorelin actually fall short?

This is the comparison most readers are really trying to sort out, so let's be honest about it. Recombinant human growth hormone (rhGH, sold as Genotropin, Norditropin, Omnitrope, and others) delivers GH directly. It bypasses the pituitary entirely. That makes it more potent and more predictable in raising IGF-1 levels, and it's the only option for patients whose pituitary can't produce GH at all (certain forms of adult and pediatric GHD, Turner syndrome, chronic kidney disease in children, and a short list of other FDA-approved indications) ^[5]. Sermorelin can't do that job in those patients. If the pituitary is significantly damaged or nonfunctional, GHRH signaling has nothing to stimulate. Sermorelin is also weaker in raw effect, it produces a more modest, physiologic rise in GH and IGF-1 compared to injecting GH directly, and clinical use for non-GHD adults remains off-label and less studied than approved rhGH use ^{[3] [4]}. Where sermorelin has an edge: cost is typically lower, the pulsatile mechanism theoretically preserves more of the body's natural feedback control, and the side effect profile in published studies tends to run milder than reports associated with supraphysiologic rhGH dosing. But if a reader is expecting sermorelin to functionally replace HGH one-for-one, that's not what the evidence supports. It's a different tool with a gentler, upstream effect, not a cheaper substitute with equivalent potency.

Can you legally buy SLU-PP-332 as a prescription like sermorelin?

No. Sermorelin can be legally prescribed and dispensed through a licensed compounding pharmacy after a provider evaluation, following FDCA compounding rules under Sections 503A/503B. That's a regulated, if off-label, pathway with a prescribing clinician and a licensed pharmacy in the chain. SLU-PP-332 has no such pathway. It's sold by research chemical suppliers explicitly labeled 'not for human consumption,' which is a legal disclaimer, not a safety guarantee. There's no FDA monograph, no compounding pharmacy formulation standard, and no clinician oversight built into that supply chain. Buying it for personal use sits entirely outside the regulatory system that exists to catch contamination, dosing errors, and mislabeled concentration, the exact problems the compounding oversight framework is designed to reduce for drugs like sermorelin.

What does typical dosing look like for each, and why does that comparison break down?

Sermorelin dosing in clinical and published off-label contexts generally falls in the range of 0.1 to 0.3 mg per day by subcutaneous injection for adults, typically given at bedtime to align with the body's natural nighttime GH pulse, based on protocols derived from GHD dosing literature ^{[3] [4]}. Pediatric Geref dosing historically ran by weight, roughly 0.03 mg/kg/day, under direct physician supervision ^[1]. SLU-PP-332 has no established human dose because it has never been dosed in a human trial. The only numbers available are mouse study doses, typically in the 3 to 20 mg/kg range depending on the specific mouse experiment ^[2], and body weight scaling from mouse to human is notoriously unreliable for translating exact doses, especially for a molecule with unknown human pharmacokinetics. Anyone quoting a 'standard SLU-PP-332 human dose' online is extrapolating from rodent data with no clinical verification behind it. If you're trying to understand how sermorelin dosing is actually calculated for an individual, the sermorelin dosage calculator walks through the weight and goal-based inputs prescribers use.

Why would anyone consider SLU-PP-332 at all, and what's the actual reasoning behind it?

The interest comes from the Nature Communications findings: mice given SLU-PP-332 ran significantly longer distances and showed a fiber-type shift toward more oxidative muscle, an effect the researchers described as pharmacologically mimicking aspects of endurance training adaptation ^[2]. That's a genuinely interesting finding for exercise physiology and metabolic disease research. It is not evidence that the same happens in humans, at what dose, or with what safety tradeoffs. Research compounds like this often take years, sometimes a decade or more, to move from a promising mouse study to even a Phase 1 human trial, and many never make that jump at all because early rodent results don't replicate in people. Sermorelin already crossed that entire bridge decades ago. Choosing between the two isn't really choosing between two treatment options; it's choosing between an established peptide with known human data and a laboratory finding that hasn't yet been tested in a single human clinical trial.

How should someone actually decide between these two, practically speaking?

If the goal is addressing a diagnosed or suspected growth hormone deficiency, sermorelin (or direct rhGH, depending on the diagnosis) is the option with a real evidence base and a legal prescribing pathway. That conversation starts with bloodwork and a provider, not a peptide seller's website. If the interest in SLU-PP-332 comes from curiosity about exercise-mimetic research, the honest answer is that it currently belongs in a lab, not a medicine cabinet. There's no dose, no safety data, and no legal human-use pathway. Waiting for actual human trials isn't overly cautious, it's just how drug development is supposed to work. For readers leaning toward sermorelin, the next steps are a conversation with a prescriber about GH-axis testing, a look at sermorelin reviews from other patients' documented experiences, and understanding sourcing quality, since compounded peptide quality varies by pharmacy. Sermorelin Co connects that conversation to a provider-reviewed path and works with a licensed fulfilling pharmacy partner, rather than shipping a research chemical with a disclaimer stapled to the label.

Frequently asked questions

Is SLU-PP-332 approved for human use anywhere?

No. As of current published literature, SLU-PP-332 has not been approved by the FDA or any comparable regulatory agency, and it has not completed a registered human clinical trial. All published data comes from mouse studies, primarily the 2023 Nature Communications paper by Billon and colleagues at Saint Louis University.

Was sermorelin ever an FDA-approved drug?

Yes. Sermorelin acetate was FDA-approved and marketed as Geref for diagnostic GH testing and pediatric growth hormone deficiency treatment. The manufacturer discontinued the branded product commercially in the mid-2000s. It was not pulled for safety reasons or an FDA-mandated recall, it was a business discontinuation.

Can sermorelin fully replace HGH injections?

Not in patients whose pituitary can't produce GH on its own. Sermorelin stimulates the pituitary to release its own growth hormone, so it depends on a functioning pituitary gland. For conditions like Turner syndrome or severe pituitary damage, direct recombinant HGH is the only option that works.

What does SLU-PP-332 actually do in the body?

In mouse studies, it activates estrogen-related receptors (ERRα, ERRβ, ERRγ), which regulate mitochondrial function and muscle fiber type. Researchers observed increased running endurance and a shift toward more oxidative, fatigue-resistant muscle fibers in mice. No human data on its effects currently exists.

Is it legal to buy SLU-PP-332 online?

It's sold by research chemical suppliers labeled 'not for human consumption,' which keeps sellers outside drug regulations but doesn't make personal use a medically supervised or legally sanctioned practice. There's no prescription pathway, no compounding pharmacy standard, and no clinician oversight involved in that supply chain.

Why did Geref get discontinued if it worked?

The manufacturer discontinued Geref commercially in the mid-2000s, most likely due to low sales volume relative to production costs and the availability of alternative GH-axis therapies, not because of a safety issue or FDA action. Sermorelin remains available today through compounding pharmacies under physician prescription.

How is sermorelin typically dosed compared to SLU-PP-332?

Sermorelin has established human dosing, roughly 0.1 to 0.3 mg per day by subcutaneous injection in adults, based on published GHD literature. SLU-PP-332 has no established human dose at all; the only figures available are mouse study doses, which don't translate reliably to human dosing.

Does sermorelin have long-term safety data?

Yes, relatively speaking. Decades of use in pediatric GHD treatment and adult off-label studies have documented common side effects like injection site reactions, flushing, and headache, with a generally manageable safety profile. It's not as extensively studied as insulin, but it has real clinical history behind it.

Is SLU-PP-332 the same class of compound as sermorelin?

No. Sermorelin is a peptide that mimics growth hormone-releasing hormone and works through the pituitary gland. SLU-PP-332 is a synthetic small molecule that activates estrogen-related receptors involved in mitochondrial and muscle metabolism. They target completely different biological pathways.

Which one is safer to try right now?

Sermorelin, without question, based on available evidence. It has decades of human use data and a legal prescribing pathway through compounding pharmacies. SLU-PP-332 has zero published human trials, meaning its human safety profile, correct dosing, and side effect risks are entirely unknown.

Does either compound have anti-aging benefits?

Neither has clinical evidence supporting anti-aging claims. Sermorelin's approved and studied uses relate to growth hormone deficiency diagnosis and treatment, not aging reversal. SLU-PP-332's mouse data concerns exercise endurance and muscle fiber type, not aging outcomes in humans, since no human studies exist at all.

Where can I get sermorelin legally?

Through a licensed prescriber who evaluates your health history and, often, GH-axis bloodwork, followed by dispensing through a licensed compounding pharmacy under FDCA Sections 503A or 503B compounding rules. That's a fundamentally different and safer path than ordering an unregulated research chemical online.

Sources

1. U.S. National Library of Medicine, DailyMed, historical label archive entry for Geref (sermorelin acetate for injection), NDA 019-826: Sermorelin was FDA-approved and marketed as Geref before being commercially discontinued
2. Billon C, et al. "Synthetic ERRα/β/γ agonist induces an ERR-dependent exercise-mimetic transcriptome in skeletal muscle." Nature Communications 14, 4364 (2023). PMID: 37474516: SLU-PP-332 activates estrogen-related receptors and increased endurance and oxidative fiber type in mice
3. Prakash A, Goa KL. "Sermorelin: a review of its use in the diagnosis and treatment of children with idiopathic growth hormone deficiency." BioDrugs. 1999;12(2):139-157. PMID: 18031160: Established sermorelin dosing ranges in pediatric and adult growth hormone deficiency literature
4. NIH National Institute of Diabetes and Digestive and Kidney Diseases, "Growth Hormone Deficiency" health topic overview: Safety profile and clinical background of GHRH-analog therapy in growth hormone deficiency
5. U.S. Food and Drug Administration, Drugs@FDA database record for Genotropin (somatropin) NDA 020280: Recombinant human growth hormone approved indications and direct GH mechanism
6. U.S. Food and Drug Administration, "Human Growth Hormone (Somatropin) and Athletic Performance" consumer safety update: FDA-approved indications and safety oversight framework for recombinant human growth hormone products